Stocks · News reference
Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207
Guggenheim analyst Delma Caiati assumes Neurocrine Biosciences (NASDAQ:NBIX) with a Buy rating and announces Price Target of $207.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — NEUROCRINE BIOSCIENCES INC (NBIX)
Filed: 2026-09-28 AccNo: 0000914475-26-000045 Size: 191 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $182 to $183.